Compounding Pharmaceutical Manufacturing White Paper 
Pharmaceutical Technology
JUNE 19, 2025
These compounds have the potential for addressing a spectrum of neuropsychiatric disorders that currently lack adequate treatment options. As well as advancing DT-101, the new capital injection will also support the progression of two gamma-aminobutyric acid type A (GABA A ) receptor modulators towards clinical trials in 2026.
European Pharmaceutical Review
DECEMBER 21, 2022
2 However, most of these efforts relating to catalysis, 3 process waste metrics, 4 lifecycle assessments, 5 pharmaceuticals in the environment 6 and the phase out of substances of concern 7 mainly mitigate the consequences of pharmaceutical manufacturing. Defossilization of pharmaceutical manufacturing. 199‒208.
Expert insights. Personalized for you.
52 
Let's personalize your content